EGFR and neoplasm: Erlotinib, EGFR inhibitor, in combination with bevacizumab/IFN (BVZ/IFN/ERLO) inhibited tumor growth, promoted blood vessel normalization and reduced lymphatic network in mouse RCC xenografts.